4 results match your criteria: "The University of Sydney at Westmead Millennium Institute for Medical Research[Affiliation]"
Cancer Epidemiol Biomarkers Prev
April 2015
Centre for Cancer Research, University of Sydney at Westmead Millennium Institute for Medical Research and Melanoma Institute Australia, Sydney, Australia.
Background: Awareness of individual risk may encourage improved prevention and early detection of melanoma.
Methods: We evaluated the accuracy of self-reported pigmentation and nevus phenotype compared with clinical assessment, and examined agreement between nevus counts from selected anatomical regions. The sample included 456 cases with invasive cutaneous melanoma diagnosed between ages 18 to 39 years and 538 controls from the population-based Australian Melanoma Family Study.
Health Expect
December 2015
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Objectives: Prostate cancer screening using prostate-specific antigen (PSA) remains controversial. In deciding about screening, men must weigh the benefits and harms: little is known about benefit: harm trade-offs men are willing to accept. The objective of this study was to assess men's preferences for PSA screening, and the trade-offs between benefits and harms men are willing to accept when deciding about screening.
View Article and Find Full Text PDFMelanoma Res
December 2013
aThe University of Sydney at Westmead Millennium Institute for Medical Research bMelanoma Institute Australia, Sydney, New South Wales, Australia.
Pigment Cell Melanoma Res
September 2013
Sydney Medical School, The University of Sydney at Westmead Millennium Institute for Medical Research, Sydney, NSW, Australia.
For disseminated melanoma, new prognostic biomarkers and therapeutic targets are urgently needed. The organization of protein-protein interaction networks was assessed via the transcriptomes of four independent studies of metastatic melanoma and related to clinical outcome and MAP-kinase pathway mutations (BRAF/NRAS). We also examined patient outcome-related differences in a predicted network of microRNAs and their targets.
View Article and Find Full Text PDF